Therapeutic and Chemopreventive Effects of Ursodeoxycholic Acid (UDCA): Potential Role in Patients with Barrett’s Esophagus
DOI:
https://doi.org/10.17140/GOJ-1-115Keywords:
Esophagus, Hepatocytes, Ursodeoxycholic acid, ChemopreventiveAbstract
Ursodeoxycholic Acid (UDCA) is widely used for the treatment of cholestatic liver diseases. Major mechanisms of this action are protection of cholangiocytes against cytotoxicity of hydrophobic bile acids, stimulation of hepatobiliary secretion, and protection of hepatocytes against bile acid induced apoptosis. UDCA has also been shown to modulate mitochondrial transmembrane potential and prevent increases in mitochondrial Reactive Oxygen Species (ROS) production. Moreover, UDCA has been shown to have a chemopreventive role in mouse models of colon cancer and in patients with primary sclerosing cholangitis and concomitant In flammatory Bowel Disease (IBD), low dose UDCA lowers the risk of IBD-associated colorectal neoplasia. Our studies suggest that oral UDCA may protect against DNA damage induced by hydrophobic bile acids such as Deoxycholic acid (DCA) in the metaplastic mucosa of patients with Barrett’s esophagus. We have found that DCA induces carcinogenic DNA damage in Barrett’s metaplasia. UDCA which counters the DNA damaging effects of DCA therefore might have a role as a chemopreventive agent in Barrett’s metaplasia. Future clinical studies on the use of UDCA for chemoprevention in patients with Barrett’s esophagus should be considered.
References
Hagey LR, Crombie DL, Espinosa E, Carey MC, Igimi H, Hofmann AF. Ursodeoxycholic acid in the Ursidae: biliary bile acids of bears, pandas, and related carnivores. J Lipid Res. 1993; 34: 1911.
Beuers U, Trauner M, Jansen P, Poupon R. New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond. J Hepatol. 2015; 62: S25. doi: 10.1016/j. jhep.2015.02.023
Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestat-ic liver disease: mechanisms of action and therapeutic use revis-ited. Hepatology. 2002; 36: 525. doi: 10.1053/jhep.2002.36088
Roma MG, Toledo FD, Boaglio AC, Basiglio CL, Crocenzi FA, Sánchez Pozzi EJ. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications. Clin Sci (Lond). 2011; 121: 523.doi: 10.1042/CS20110184
Tanaka H, Makino I. Ursodeoxycholicacid-dependent activa-tion of the glucocorticoid receptor. Biochem Biophys Res Com-mun. 1992; 188: 942. doi: 10.1016/0006-291X(92)91146-H
Solá S, Amaral JD, Castro RE, et al. Nuclear translocation of UDCA by the glucocorticoid receptor is required to reduce TGF-beta1-induced apoptosis in rat hepatocytes. Hepatology. 2005; 42: 925. doi: 10.1002/hep.20870
Rodrigues CM, Fan G, Wong PY, Kren BT, Steer CJ. Ursode-oxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reac-tive oxygen species production. Mol Med. 1998; 4: 165.
Bernardes-Silva CF, Damião AO, Sipahi AM, et al. Ursode-oxycholic acid ameliorates experimental ileitis counteracting intestinal barrier dysfunction and oxidative stress. Dig Dis Sci. 2004; 49: 1569. doi: 10.1023/B:DDAS.0000043365.39251.6e
Araki Y, Andoh A, Bamba H, et al. The cytotoxicity of hydro-phobic bile acids is amelioratedby more hydrophilic bile acids in intestinal cell lines IEC-6 and Caco-2. Oncol Rep. 2003; 10: 1931. doi: 10.3892/or.10.6.1931
Wali RK, Frawley BP Jr, Hartmann S, et al. Mechanism of action of chemoprotectiveursodeoxycholate in the azoxymeth-anemodel of rat colonic carcinogenesis: potential roles of pro-teinkinase C-alpha, -beta II, and -zeta. Cancer Res. 1995; 55: 5257.
Narisawa T, Fukaura Y, Terada K, Sekiguchi H. Prevention of N-methylnitrosourea-induced colon tumorigenesis by ursode-oxycholic acid in F344 rats. Jpn J Cancer Res. 1998; 89: 1009.
Singh S, Khanna S, Pardi DS, Loftus EV Jr, Talwalkar JA. Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patientswith primary sclerosing cholangitis and inflammatory bowel disease: asystematic review and meta-analysis. Inflamm Bowel Dis. 2013; 19: 1631. doi: 10.1097/ MIB.0b013e318286fa61
Hill MJ, Melville DM, Lennard-Jones JE, Neale K, Ritchie JK. Faecal bile acids, dysplasia, and carcinoma in ulcerative coli-tis. Lancet. 1987; 2: 185. doi: 10.1016/S0140-6736(87)90766-5
Batta AK, Salen G, Holubec H, Brasitus TA, Alberts D, Ear-nest DL. Enrichment of the more hydrophilic bile acid ursode-oxycholic acid in the fecal water-soluble fraction after feeding to rats with colon polyps. Cancer Res. 1998; 58: 1684.
Wali RK, Frawley BP Jr, Hartmann S, et al. Mechanism of action of chemoprotectiveursodeoxycholate in the azoxymeth-ane model of rat colonic carcinogenesis: potential roles of pro-tein kinase C-alpha, -beta II, and -zeta. Cancer Res. 1995; 55: 5257.
Ikegami T, Matsuzaki Y, Shoda J, Kano M, Hirabayashi N, Tanaka N. The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats: suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue. Cancer Lett. 1998; 134: 129. doi: 10.1016/S0304-3835(98)00248-1
Kusunoki M, Sakanoue Y, Hatada T, Yanagi H, Yama-mura T, Utsunomiya J. Protein kinase C activity in human colonic adenoma and colorectal carcinoma. Cancer. 1992; 69: 24. doi: 10.1002/1097-0142(19920101)69:1<24::AID-CNCR2820690107>3.0.CO;2-1
Kopp R, Noelke B, Sauter G, Schildberg FW, Paumgartner G, Pfeiffer A. Alteredprotein kinase C activity in biopsies of hu-man colonic adenomas and carcinomas. Cancer Res. 1991; 51: 205.
Hendrickse CW, Radley S, Donovan IA, Keighley MR, Ne-optolemos JP. Activities of phospholipase A2 and diacylglycerol lipase are increased in human colorectal cancer. Br J Surg. 1995; 82: 475. doi: 10.1002/bjs.1800820415
Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association technical review on the management of Barrett’s esophagus. Gastroenterology. 2001; 140: e18. doi: 10.1053/j.gastro.2011.01.031
Pohl H, Sirovich B, Welch HG. Esophageal adenocarci-noma incidence:are we reaching the peak? Cancer Epidemiol Biomarkers Prev. 2010; 19: 1468. doi: 10.1158/1055-9965.EPI-10-0012
Nehra D, Howell P, Williams CP, Pye JK, Beynon J. Toxic bile acids in gastro-oesophageal reflux disease: influence of gas-tric acidity. Gut. 1999; 44: 598.
Vaezi MF, Richter JE. Role of acid and duodenogastroesoph-ageal reflux in gastroesophageal reflux disease. Gastroenterol-ogy. 1996; 111: 1192. doi: 10.1053/gast.1996.v111.pm8898632
Huo X, Juergens S, Zhang X, et al. Deoxycholic acid causes dna damage while inducing apoptotic resistance through nf-kap-pa b activation in benign barrett’s epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2011; 301: G278. doi: 10.1152/ajp-gi.00092.2011
Peng S, Huo X, Rezaei D, Zhang Q, et al. In Barrett’s esoph-agus patients and Barrett’s cell lines, ursodeoxycholic acid in-creases antioxidant expression and prevents DNA damage by bile acids. Am J Physiol Gastrointest Liver Physiol. 2014; 307: G129. doi: 10.1152/ajpgi.00085.2014
Kowdley KV. Ursodeoxycholic acid therapy in hepatobi-liary disease. Am J Med. 2000; 108: 481. doi: 10.1016/S0002- 9343(00)00318-1
Bonner WM, Redon CE, Dickey JS, et al. GammaH2AX and cancer. Nat Rev Cancer. 2008; 8: 957. doi: 10.1038/nrc2523
Mills KD, Ferguson DO, Alt FW. The role of DNA breaks in genomic instability and tumorigenesis. Immunol Rev. 2003; 194: 77. doi: 10.1034/j.1600-065X.2003.00060.x
Albino AP, Huang X, Jorgensen E, Yang J, Gietl d, Traganos F, Darzynkiewicz Z. Induction of H2AX phosphorylation in pul-monary cells by tobacco smoke: a new assay for carcinogens. Cell Cycle. 2004; 3: 1062. doi: 10.4161/cc.3.8.988
Bozikas A, Marsman WA, Rosmolen WD, et al. The effect of oral administration of ursodeoxycholic acid and high-dose proton pump inhibitors on the histology of Barrett’s esopha-gus. Dis Esophagus. 2008; 21: 346. doi: 10.1111/j.1442- 2050.2007.00782.x
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Gastro (GOJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.